Myeloproliferative Neoplasms
The latest news, research, and perspectives in myeloproliferative neoplasms (MPNs). MPNs occur when the bone marrow produces too many red blood cells, platelets, or certain white blood cells. The primary subtypes include myelofibrosis, polycythemia vera, and essential thrombocythemia.
Fedratinib reduced spleen size and symptoms in ruxolitinib-pretreated myelofibrosis patients in FREEDOM2 trial.
PXS-5505 shows promise in ruxolitinib-refractory myelofibrosis, improving symptoms and reducing bone marrow fibrosis.
The phase 3 SENTRY trial will randomize patients to ruxolitinib plus placebo or selinexor plus placebo.
Cardiovascular complications, such as those associated with arterial or venous thromboembolism, are a prominent concern.
Ruchi Desai, MD, specifies what improvements are needed today in the therapy options available for myelofibrosis.
Ruchi Desai, MD, speaks on the challenges of clinical evaluation and therapy optimization in myelofibrosis.
From Buffalo to the Manhattan borough, Dr. Rampal shares his journey to becoming a hematologist-oncologist.
Nuvisertib, an oral, investigational, highly selective PIM1 kinase inhibitor, showed clinical activity in a phase 1/2 study.
Dr. John Mascarenhas discussed novel type 2 JAK inhibitors for myelofibrosis, such as AJ1-11095 and INCB160058.
End Point Success Varies in a Phase 3 Trial of Luspatercept Plus JAK Inhibitor Therapy for MF Anemia
The combination did not meet the primary end point for RBC transfusion independence but still markedly improved anemia.
Gaps in coordination and collaboration between primary care and oncology may impact long-term survival outcomes for patients.
In the SURPASS ET trial, ropeginterferon alfa-2b was compared to anagrelide in second-line management of ET.
Dose escalation study data presented at EHA2025 showed durable response in patients with disease resistant to prior therapy.
The agent, nuvisertib, previously received Orphan Drug Designation from the FDA for this indication in May 2022.
The phase 3 SURPASS-ET trial presented at ASCO evaluated ropeginterferon alfa-2b versus anagrelide for the treatment of ET.
Expert insights from a HemOnc Pulse Live! session offer a compelling look at where CML and MPN care is headed.
How have TKIs transformed CML survival and what’s next for treatment-free remission and deeper MPN responses?
100% MRD-negative CR in Ph+ ALL? Dr. Catherine Lai recaps standout abstracts from an ASCO rapid oral session.
Gecacitinib improved spleen volume, symptoms, and anemia in JAK inhibitor–naive MF, regardless of baseline anemia severity.
The MANIFEST-2 trial compares pelabresib plus ruxolitinib with placebo plus ruxolitinib in JAK-inhibitor-naive myelofibrosis.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.